Premium
Detection of minimal residual disease in B lymphoblastic leukemia using vi SNE
Author(s) -
DiGiuseppe Joseph A.,
Tadmor Michelle D.,
Pe'er Dana
Publication year - 2015
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21252
Subject(s) - immunophenotyping , minimal residual disease , medicine , bone marrow , leukemia , lymphoblastic leukemia , oncology , population , flow cytometry , pathology , immunology , environmental health
Background Minimal residual disease (MRD) following treatment is a robust prognostic marker in B lymphoblastic leukemia. However, the detection of MRD by flow cytometric immunophenotyping is technically challenging, and an automated method to detect MRD is therefore desirable. viSNE, a recently developed computational tool based on the t‐Distributed Stochastic Neighbor Embedding (t‐SNE) algorithm, has been shown to be capable of detecting synthetic “MRD‐like” populations of leukemic cells created in vitro, but whether viSNE can facilitate the immunophenotypic detection of MRD in clinical samples has not been evaluated. Methods We applied viSNE retrospectively to 8‐color flow cytometric immunophenotyping data from normal bone marrow samples, and samples from B lymphoblastic leukemia patients with or without suspected MRD on the basis of conventional manual gating. Results In each of 14 bone marrow specimens containing MRD or suspected MRD, viSNE identified a putative MRD population; an abnormal composite immunophenotype was confirmed for the putative MRD in each case. MRD populations were not identified by viSNE in control bone marrow samples from patients with increased normal B‐cell precursors, or in post‐treatment samples from B lymphoblastic leukemia patients who did not have detectable MRD by manual gating. Conclusion viSNE shows promise as an automated method to facilitate immunophenotypic MRD detection in patients treated for B lymphoblastic leukemia. © 2015 International Clinical Cytometry Society